Owlstone Medical presenting at Nano World Cancer Day 2016
The University of Liverpool, London, 02 Feb 2016
Billy Boyle, co-founder of Owlstone Medical will present at Nano World Cancer Day on 2nd February 2016 in London. Focussing on the need for an extremely sensitive, accurate and fast means of identifying chemical biomarkers, Billy will present Owlstone Medical's cancer breathalyzer system and lay out the company's vision: save 100,000 lives and save $1.5B in health care costs by 2020.
Nanomedicine is nanotechnology applied to innovation in impacts virtually all therapeutic areas, including oncology, diseases and neurologic disorders. With approximately 50 products already on the market and 200 more undergoing clinical trials, nanomedicine is already showing its benefits to patients.
The most active and promising area of nanomedicine research is cancer. Cancer is targeted by 31% of the nanomedicine products under clinical trials which have been developed for diagnostics, treatment and monitoring of patients.
The 3rd edition of the Nano World Cancer Day (NWCD) is taking place simultaneously in 12 countries including Austria, Czech Republic, Finland, France, Germany, Greece, Italy, Ireland, Luxembourg, Netherlands, Norway, Portugal, and the United Kingdom.
2nd February 2016 at The University of Liverpool in London, 33 Finsbury Square, London EC2A 1AG